Search company, investor...
Xlumena company logo


Founded Year



Acquired | Acquired

Total Raised


About Xlumena

Xlumena is developing products that enable advanced image-guided endoscopy procedures. These products will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions.

Headquarters Location

453 Ravendale Drive Suite H

Mountain View, California, 94043,

United States


Missing: Xlumena's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Xlumena's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Xlumena

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xlumena is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,312 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Xlumena Patents

Xlumena has filed 1 patent.

The 3 most popular patent topics include:

  • Digestive system
  • Hepatology
  • Implants (medicine)
patents chart

Application Date

Grant Date


Related Topics




Digestive system, Endoscopy, Hepatology, Digestive system surgery, Inflammations


Application Date


Grant Date



Related Topics

Digestive system, Endoscopy, Hepatology, Digestive system surgery, Inflammations



Latest Xlumena News

BSX pays $63m for Xlumena | The week in medtech M&A

Apr 8, 2015

Tweet April 8, 2015 by MassDevice Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Boston Scientific ponies up $63m for Xlumena; Uroplasty, Vision-Sciences merge as Cogentix; Medtronic buys Dutch diabetes clinic; Integra LifeSciences readies SeaSpine spinout; Cogentix shifts Mass. manufacturing plant April 1, 2015 by Brad Perriello Boston Scientific today said it agreed to pay $62.5 million up front for Xlumena and its Axios line of biliary devices, putting at least another $12.5 million on the table in potential milestones. Mountain View, Calif.-based Xlumena makes the Axios and Hot Axios stenting systems, which won CE Mark approval in the European Union for transgastric or transduodenal endoscopic drainage of pancreatic pseudocysts or the biliary tract, Boston Scientific said. Read more

Xlumena Frequently Asked Questions (FAQ)

  • When was Xlumena founded?

    Xlumena was founded in 2007.

  • Where is Xlumena's headquarters?

    Xlumena's headquarters is located at 453 Ravendale Drive, Mountain View.

  • What is Xlumena's latest funding round?

    Xlumena's latest funding round is Acquired.

  • How much did Xlumena raise?

    Xlumena raised a total of $53.07M.

  • Who are the investors of Xlumena?

    Investors of Xlumena include Boston Scientific, Charter Life Sciences, Ascent Biomedical Ventures, Prism VentureWorks, Aperture Venture Partners and 5 more.

  • Who are Xlumena's competitors?

    Competitors of Xlumena include GENICON, Acelity, Calibra Medical, Avantis Medical Systems, Entellus Medical and 12 more.

Compare Xlumena to Competitors

Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment.Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

Cambridge Endoscopic Devices

Cambridge Endoscopic Devices (CED) has developed a line of surgical instruments that aim to address the need for enhanced dexterity and manipulation in laparoscopic and endoscopic surgery. Per the company, these instruments overcome surgical barriers encountered with traditional endoscopic and laparoscopic instruments, allowing for the potential of new surgical procedures and better, more cost effective clinical outcomes.


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Pavad Medical

Pavad develops medical devices for the treatment of sleep apnea.

Cord Blood Registry Logo
Cord Blood Registry

Cord Blood Registry (CBR) is a newborn stem cell company. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.


CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.